3 Reasons Pfizer Inc.'s Stock Could Fall
Despite rumors about mergers and acquisitions, these three catalysts could wind up pressuring Pfizer's stock and ultimately pushing it lower.
Should Gilead Sciences, inc. Fear This New Competitor Drug?
GlaxoSmithKline and Pfizer's ViiV have won approval for a new HIV therapy that may work better than Gilead's Atripla.